Download fulltext
HTML
Bahreiny, S. S., Ahangarpour, A., Hemmati, A. A., Kazemzadeh, R., Bastani, M.-N., Dabbagh, M. R., & Aghaei, M. (2023). Circulating nesfatin-1 levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. International Journal of Reproductive BioMedicine (IJRM), 21(10), 777–788. https://doi.org/10.18502/ijrm.v21i10.14533
https://doi.org/10.18502/ijrm.v21i10.14533
statistics
- 124 Abstract Views
- 58 PDF Views
- 0 HTML Views
- Cited by 1 article
authors
-
Seyed Sobhan Bahreiny
Seyed Sobhan Bahreiny
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
-
Akram Ahangarpour
Akram Ahangarpour
Medical Basic Sciences Research Institute, Physiology Research Center, Department of Physiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
-
Ali Asghar Hemmati
Ali Asghar Hemmati
Marine Pharmaceutical Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
-
Razieh Kazemzadeh
Razieh Kazemzadeh
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
-
Mohammad-Navid Bastani
Mohammad-Navid Bastani
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
-
Mohammad Reza Dabbagh
Mohammad Reza Dabbagh
Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
-
Mojtaba Aghaei
Mojtaba Aghaei
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Published Date
- Nov 21, 2023
Circulating nesfatin-1 levels in women with polycystic ovary syndrome: A systematic review and meta-analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in females. Nesfatin-1 is a neuropeptide synthesized in the hypothalamus and other peripheral organs, and there are conflicting opinions about its correlation with PCOS.
Objective: This study aims to investigate the correlation between nesfatin-1 and PCOS and evaluates the effectiveness of nesfatin-1 as a biomarker for the detection of PCOS in women.
Materials and Methods: A systematic review and meta-analysis were conducted to identify pertinent articles from databases such as PubMed, Web of Science, Cochrane, EMBASE, Scopus, and Google Scholar. The standardized mean difference (SMD) and 95% confidence interval (CI) were calculated using a random effects model to compare group outcomes. Additionally, meta-regression and subgroup analysis were performed to elucidate sources of heterogeneity.
Results: The meta-analysis involved 12 studies with 1222 participants, and the findings revealed a significant relationship between PCOS and nesfatin-1 levels. The pooled (SMD = 0.54; 95% CI: 0.00-1.07; p = 0.04) indicated a significant difference between the evaluated groups. Moreover, a subgroup analysis showed that there was a substantial difference in nesfatin-1 levels among women with PCOS and higher homeostatic model assessment for insulin resistance ratio (SMD = 1.46; 95% CI: 0.92-2.00; p < 0.001).
Conclusion: Our meta-analysis indicates an association between high nesfatin-1 levels and PCOS. This suggests a potential role of nesfatin-1 in the development of PCOS and proposes it as a potential diagnostic biomarker for the disease. However, further research is necessary to validate these findings.
Key words: Polycystic ovary syndrome, Insulin resistance, Body mass index, Meta-analysis.
References
[1] McGowan MP. Polycystic ovary syndrome: A common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med 2011; 13: 289–301.
[2] Regidor P-A, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Egea FM. Chronic inflammation in PCOS: The potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci 2020; 22: 384.
[3] Wilkes S, Murdoch A. Obesity and female fertility: A primary care perspective. J Fam Plann Reprod Health Care 2009; 35: 181–185.
[4] Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: A practical guide. Drugs 2006; 66: 903–912.
[5] Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113– 116.
[6] Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141–154.
[7] Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29: 841–852.
[8] Sulaiman NS, Rovina K, Joseph VM. Classification, extraction and current analytical approaches for detection of pesticides in various food products. J Consumer Protect Food Safety 2019; 14: 209–221.
[9] Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 2012; 42: 694–699.
[10] Fernandez-Fernandez R, Martini AC, Navarro VM, Castellano JM, Dieguez C, Aguilar E, et al. Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 2006; 254–255: 127–132.
[11] Ademoglu EN, Gorar S, Carlioglu A, Yazici H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest 2014; 37: 715–719.
[12] Stengel A. Nesfatin-1 - more than a food intake regulatory peptide. Peptides 2015; 72: 175–183.
[13] Prinz P, Goebel-Stengel M, Teuffel P, Rose M, Klapp BF, Stengel A. Peripheral and central localization of the nesfatin-1 receptor using autoradiography in rats. Biochem Biophys Res Commun 2016; 470: 521–527.
[14] Bani Mohammad M, Majdi Seghinsara A. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev 2017; 18: 17–21.
[15] Alp E, Gormus U, Guducu N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 543–547.
[16] Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: Anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039–1042.
[17] Oh-I Sh, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709–712.
[18] Taskin MI, Eser B, Adali E, Kara H, Cuce C, Hismiogullari AA. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 46–50.
[19] Bahreiny SS, Dabbagh MR, Ebrahimi R, Harooni E. Prevalence of autoimmune thyroiditis in women with polycystic ovary syndrome: A systematic review and meta-analysis. Iran J Obstet Gynecol Infertil 2023; 26: 94–106.
[20] Xu Y, Zhang H, Li Q, Lao K, Wang Y. The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat. Gynecol Endocrinol 2017; 33: 438–441.
[21] Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, et al. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci 2015; 15: 57–63.
[22] Varli B, Sukur YE, Ozmen B, Erguder BI, Sonmezer M, Berker B, et al. Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. Clin Exp Reprod Med 2021; 48: 368.
[23] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. BMJ 2009; 339: b2535.
[24] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603– 605.
[25] Hamed EA, Sayyed HG, Abbas AM, Gaber MMA, Aleem H. Nesfatin-1, dopamine, and NADPH levels in infertile women with polycystic ovary syndrome: Is there a relationship between their levels and metabolic and hormonal variables. J Reprod Infertil 2022; 23: 160–168.
[26] Faeza F, Saxena P, Jain A. Correlation of serum nesfatin- 1 level with metabolic and clinical parameters in Indian women with and without polycystic ovarian syndrome. Int J Reprod Contracep Obstet Gynecol 2023; 12: 427–431.
[27] Wang Y, Ma X, Luo J, Wang X, Han L. Expression of serum PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome. Cell Mol Biol 2022; 67: 57–63.
[28] Ali EA, AL-Jedda WA, AL-Khateeb SM, AL-Samarriae AY. The association between serum nesfatin-1 level and BMI in Iraqi patients with polycystic ovary syndrome (PCOS). Indian J Forensic Med Toxicol 2021; 15: 1490–1495.
[29] Demir Çaltekin M, Caniklioglu A, Yalcin SE, Kirmizi DA, Baser E, Yalvac ES. DLK1 and nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study. Turk J Obstet Gynecol 2021; 18: 124–130.
[30] Binnetoglu E, Erbag G, Gencer M, Turkon H, Asik M, Gunes F, et al. Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea 2014; 30: 201–204.
[31] Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41.
[32] Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106: e1071–e1083.
[33] Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides 2014; 56: 94–110.
[34] Bahreiny SS, Harooni E, Dabbagh MR, Ebrahimi R. Circulating serum preptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod BioMed 2023; 21: 367–378.
[35] Mierzynski R, Poniedzialek-Czajkowska E, Dluski D, Patro-Malysza J, Kimber-Trojnar Z, Majsterek M, et al. Nesfatin-1 and vaspin as potential novel biomarkers for the prediction and early diagnosis of gestational diabetes mellitus. Int J Mol Sci 2019; 20: 159.
[36] Rocco ER, Mory DB, Bergamin CS, Valente F, Miranda VL, Calegare BFA, et al. Optimal cutoff points for body mass index, waist circumference and HOMA-IR to identify a cluster of cardiometabolic abnormalities in normal glucose-tolerant Brazilian children and adolescents. Arq Bras Endocrinol Metab 2011; 55: 638–645.
[2] Regidor P-A, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Egea FM. Chronic inflammation in PCOS: The potential benefits of specialized pro-resolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci 2020; 22: 384.
[3] Wilkes S, Murdoch A. Obesity and female fertility: A primary care perspective. J Fam Plann Reprod Health Care 2009; 35: 181–185.
[4] Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: A practical guide. Drugs 2006; 66: 903–912.
[5] Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113– 116.
[6] Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141–154.
[7] Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29: 841–852.
[8] Sulaiman NS, Rovina K, Joseph VM. Classification, extraction and current analytical approaches for detection of pesticides in various food products. J Consumer Protect Food Safety 2019; 14: 209–221.
[9] Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 2012; 42: 694–699.
[10] Fernandez-Fernandez R, Martini AC, Navarro VM, Castellano JM, Dieguez C, Aguilar E, et al. Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 2006; 254–255: 127–132.
[11] Ademoglu EN, Gorar S, Carlioglu A, Yazici H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest 2014; 37: 715–719.
[12] Stengel A. Nesfatin-1 - more than a food intake regulatory peptide. Peptides 2015; 72: 175–183.
[13] Prinz P, Goebel-Stengel M, Teuffel P, Rose M, Klapp BF, Stengel A. Peripheral and central localization of the nesfatin-1 receptor using autoradiography in rats. Biochem Biophys Res Commun 2016; 470: 521–527.
[14] Bani Mohammad M, Majdi Seghinsara A. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev 2017; 18: 17–21.
[15] Alp E, Gormus U, Guducu N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 543–547.
[16] Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: Anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039–1042.
[17] Oh-I Sh, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709–712.
[18] Taskin MI, Eser B, Adali E, Kara H, Cuce C, Hismiogullari AA. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 46–50.
[19] Bahreiny SS, Dabbagh MR, Ebrahimi R, Harooni E. Prevalence of autoimmune thyroiditis in women with polycystic ovary syndrome: A systematic review and meta-analysis. Iran J Obstet Gynecol Infertil 2023; 26: 94–106.
[20] Xu Y, Zhang H, Li Q, Lao K, Wang Y. The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat. Gynecol Endocrinol 2017; 33: 438–441.
[21] Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, et al. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci 2015; 15: 57–63.
[22] Varli B, Sukur YE, Ozmen B, Erguder BI, Sonmezer M, Berker B, et al. Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. Clin Exp Reprod Med 2021; 48: 368.
[23] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. BMJ 2009; 339: b2535.
[24] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603– 605.
[25] Hamed EA, Sayyed HG, Abbas AM, Gaber MMA, Aleem H. Nesfatin-1, dopamine, and NADPH levels in infertile women with polycystic ovary syndrome: Is there a relationship between their levels and metabolic and hormonal variables. J Reprod Infertil 2022; 23: 160–168.
[26] Faeza F, Saxena P, Jain A. Correlation of serum nesfatin- 1 level with metabolic and clinical parameters in Indian women with and without polycystic ovarian syndrome. Int J Reprod Contracep Obstet Gynecol 2023; 12: 427–431.
[27] Wang Y, Ma X, Luo J, Wang X, Han L. Expression of serum PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome. Cell Mol Biol 2022; 67: 57–63.
[28] Ali EA, AL-Jedda WA, AL-Khateeb SM, AL-Samarriae AY. The association between serum nesfatin-1 level and BMI in Iraqi patients with polycystic ovary syndrome (PCOS). Indian J Forensic Med Toxicol 2021; 15: 1490–1495.
[29] Demir Çaltekin M, Caniklioglu A, Yalcin SE, Kirmizi DA, Baser E, Yalvac ES. DLK1 and nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study. Turk J Obstet Gynecol 2021; 18: 124–130.
[30] Binnetoglu E, Erbag G, Gencer M, Turkon H, Asik M, Gunes F, et al. Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea 2014; 30: 201–204.
[31] Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41.
[32] Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106: e1071–e1083.
[33] Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides 2014; 56: 94–110.
[34] Bahreiny SS, Harooni E, Dabbagh MR, Ebrahimi R. Circulating serum preptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Reprod BioMed 2023; 21: 367–378.
[35] Mierzynski R, Poniedzialek-Czajkowska E, Dluski D, Patro-Malysza J, Kimber-Trojnar Z, Majsterek M, et al. Nesfatin-1 and vaspin as potential novel biomarkers for the prediction and early diagnosis of gestational diabetes mellitus. Int J Mol Sci 2019; 20: 159.
[36] Rocco ER, Mory DB, Bergamin CS, Valente F, Miranda VL, Calegare BFA, et al. Optimal cutoff points for body mass index, waist circumference and HOMA-IR to identify a cluster of cardiometabolic abnormalities in normal glucose-tolerant Brazilian children and adolescents. Arq Bras Endocrinol Metab 2011; 55: 638–645.